Moteur de recherche d’entreprises européennes
Financement de l’UE (12 M €) : Déterminants exposomiques humains des maladies à médiation immunitaire Hor 01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Déterminants exposomiques humains des maladies à médiation immunitaire
Immune-mediated diseases (IMDs) are increasing rapidly in the developed countries constituting a huge medical, economic and societal challenge. The reasons to this epidemic are not known, but exposome needs to play an important role since genetic factors cannot explain such a rapid change. In the HEDIMED project altogether 20 academic and industrial partners will join their multidisciplinary and supplementary forces to identify exposomic determinants which are driving this epidemic. The project is based on a combination of data and biological samples from large clinical cohorts constituting the largest clinical resource in this field including 350.000 pregnant women, 28.000 children prospectively followed from birth and 6.600 children from cross-sectional studies. HEDIMED focuses on common chronic IMDs that cause a significant disease burden, including type 1 diabetes, celiac disease, allergies and asthma. Exposomic disease determinants and the underlying biological pathways will be identified by exploratory approach using advanced omics and multiplex technologies combined with cutting–edge datamining technologies. Particular emphasis is paid on early fetal and childhood exposome since the disease process is known to start early. Inclusion of several IMDs makes it possible to identify determinants that are common for many IMDs facilitating the development of widely operating treatments. HEDIMED includes also data and samples from clinical trials that have used exposomice interventions and cell and organ culture models to help the identification of causal associations. HEDIMED will generate an open-access toolbox that offers various kind of data, new technologies, interactions forums, latest information and functional tools for several stakeholders to facilitate the efforts to find ways to control the IMD epidemic. HEDIMED will generate several innovations which can become exploited widely in diagnostic, therapeutic, preventive and health-economical applications. HEDIMED will work together with the other projects (EXPANSE, HEAP, ATHLETE, EQUAL-LIFE, LONGITOOLS, EPHOR, REMEDIA and EXIMIOUS) funded within the Human Exposome programme call H2020 SC1-BHC-2018-2020, in order to achieve collaboration and synergy
| Baylor College OF Medicine | 596 873 € |
| Ceska Zemedelska Univerzita V Praze | 298 436 € |
| Csem Centre Suisse D'Electronique ET DE Microtechnique SA - Recherche ET Developpement | 355 930 € |
| Den Selvejende Institution Dansk Borneastma Center | 392 665 € |
| Empirica Gesellschaft FUR Kommunikations UND Technologieforschung mbH | 249 573 € |
| Folkehelseinstituttet | 623 374 € |
| Gnomon Plirophorikis ΑΕ | 279 859 € |
| Helsingin Yliopisto | 482 243 € |
| Lunds Universitet | 659 457 € |
| Luonnonvarakeskus | 232 655 € |
| Oulun Yliopisto | 287 096 € |
| Pirkanmaan Hyvinvointialue | 414 205 € |
| Region Skane | 0,00 € |
| SA Tartu Ulikooli Kliinikum | 467 550 € |
| Tampereen Korkeakoulusaatio sr | 1 526 088 € |
| Tartu Ulikool | 417 811 € |
| Technische Universitaet Graz | 470 234 € |
| Teknologian Tutkimuskeskus VTT Oy | 1 004 254 € |
| Terramonitor Oy | 219 351 € |
| Terveyden JA Hyvinvoinnin Laitos | 580 675 € |
| Turun Yliopisto | 1 160 371 € |
| Universita Degli Studi Di Siena | 457 603 € |
| Univerzita Karlova | 816 038 € |
https://cordis.europa.eu/project/id/874864
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.